atropine hydrochloride | 58116-46-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: atropine hydrochloride
• CAS: 58116-46-4
• 化学式: C₁₇H₂₃NO₃*ClH
• 分子量: 325.835
• InChiKey: OJIPQOWZZMSBGY-RIMUKSHESA-N

反应信息

• 作为反应物：
  描述：

  苯甲酰氯 、 atropine hydrochloride 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Schmidt, Archiv der Pharmazie, 1894, vol. 232, p. 430

  摘要：

  DOI：
• 作为产物：
  描述：

  (2S,3R)-<1-14C,3-3H>phenylalanine 在 盐酸 、 sodium hydroxide 作用下， 生成 atropine hydrochloride 、 Scopolamine hydrochloride 、 <1-14C>atropine hydrochloride 、
  参考文献：
  名称：

  Leete, Edward, Canadian Journal of Chemistry, 1987, vol. 65, p. 226 - 228

  摘要：

  DOI：

文献信息

• Substituted 1,3-thiazole compounds, their production and use
  申请人：——

  公开号：US20040053973A1

  公开（公告）日：2004-03-18

  (1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.

  (1) 一种1,3-噻唑化合物，其5位被取代为含有一个取代基的4-吡啶基团，该取代基不包括芳香基，或者(2) 一种1,3-噻唑化合物，其5位被取代为一个吡啶基团，该吡啶基团的氮原子邻近位置有一个取代基，该取代基不包括芳香基，具有出色的p38 MAP激酶抑制活性。
• [EN] GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO<br/>[FR] ANTAGONISTES DES RECEPTEURS DES HORMONES LIBERANT DES GONADOTROPINES ET PROCEDES CONNEXES
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2005007633A1

  公开（公告）日：2005-01-27

  GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein n, R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  抑制性激素释放激素受体拮抗剂已经被披露，可用于治疗男性和女性的多种与性激素相关的疾病。本发明的化合物具有以下结构：其中n、R1a、R1b、R1c、R2a、R2b、R3、R4、R5、R6和X如本文所定义，包括立体异构体、前药和其药用可接受的盐。还披露了含有本发明化合物的组合物，以及与药用可接受载体结合的方法，用于拮抗需要的受试者体内的促性腺激素释放激素。
• [EN] MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS DE LACTONE MACROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ELIXIR MEDICAL CORP

  公开号：WO2009114010A1

  公开（公告）日：2009-09-17

  The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula (I) wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, -OH, -OP(O)Me2, (II), (III), -O-(CH2)n-OH and -O-(CH2)m-O-(CH2)o-CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of (IV) and (V) wherein each M8 is independently a member selected from the group consisting Of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of (VI), (VII) and (VIII); and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.

  本发明提供了一种制药组合物，该组合物包括一种药用可接受的赋形剂和一种式(I)的化合物，其中R1、R2、R3、R5、R6、R8、M1、M2、M3、M4、M5、M6和M7各自独立地选择自H、C1-6烷基、OH和C1-6羟基烷基的群体中的一种；R4、R7和R9各自独立地选择自C1-6烷氧基和OH的群体中的一种；R10选择自H、-OH、-OP(O)Me2、(II)、(III)、-O-(CH2)n-OH和-O-( )m-O-( )o-CH3的群体中的一种，其中下标n和m各自独立地从2到8，下标o从1到6；L1和L4各自独立地选择自(VI)和(VII)的群体中的一种，其中每个M8各自独立地选择自C1-6烷基、OH和C1-6羟基烷基的群体中的一种；L2和L3各自独立地选择自(VI)、(VII)和(VIII)的群体中的一种；以及其盐、水合物、异构体、代谢物、N-氧化物和前药。
• Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
  申请人：Huang Q. Charles

  公开号：US20060122204A1

  公开（公告）日：2006-06-08

  GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein n, R 1a , R 1b , R 1c , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  本发明揭示了GnRH受体拮抗剂，其在男性和女性的多种性激素相关疾病治疗中具有用途。本发明的化合物具有以下结构：其中n，R1a，R1b，R1c，R2a，R2b，R3，R4，R5，R6和X如本文所定义，包括立体异构体，前药和其药学上可接受的盐。还揭示了含有本发明化合物与药学上可接受的载体结合的组合物，以及与其相关的方法，用于拮抗需要此类物质的受体释放性激素。
• FUNCTIONAL ORAL PREPARATIONS
  申请人：SEIREN CO., LTD.

  公开号：EP1201245A1

  公开（公告）日：2002-05-02

  Provided are novel colon cancer preventives, and digestible food/drink additives and health supplements which not only are effective in body weight control and constipation prevention/treatment, but also have the action of accelerating the intestinal absorption of minerals. Sericin or it's hydrolyzed product is used as a colon cancer preventive, food/drink additive or health supplement.

  本研究提供了新型结肠癌预防剂、易消化食品/饮料添加剂和保健品，它们不仅能有效控制体重和预防/治疗便秘，还具有加速肠道吸收矿物质的作用。 丝胶或其水解产品可用作结肠癌预防剂、食品/饮料添加剂或保健品。